Kornimate/medical-research-clean huggingface dataset:
cognitive rehabilitation group intervention for breast cancer survivors

Conditions: Breast Cancer

Summary: there are over 2 million breast cancer survivors in the us today. along with extended survival, many women experience short and long-term after effects of treatment, which may decrease their quality of life and contribute to other health problems. cognitive complaints---difficulties with memory, concentration, and planning-are commonly reported after adjuvant treatments for breast cancer. this study is designed to test the efficacy of a 5 week group-based cognitive rehabilitation intervention on improving cognitive complaints and test performance, in comparison to women who will receive the same intervention at a later time (wait-list control). women will also have an eeg test performed before and after the intervention program to see if improvements in cognitive complaints and performance can be documented by examining the eeg.

previous pilot work (non-randomized, pre-post design) has shown that this intervention was effective in improving post-intervention cognitive complaints and neuropsychological (np) test performance. because practice effects may influence np performance, it is important to compare the intervention participants to women who are not exposed to the intervention. thus, this randomized controlled trial will compare the active intervention to a control group of patients who will receive the intervention at a delayed time point. the primary outcomes are improvements in cognitive complaints and np test performance 2 months after completion of the intervention program. quantitative eeg (qeeg) measurements will be used as a secondary exploratory endpoint to see if this may be an effective biomarker of cognitive performance.

Eligibility criteria:
inclusion criteria: * age 21-65 years * stage i, ii, iii breast cancer diagnosis within the past 18 months to 5 years * currently disease free, but may be on endocrine therapy * with evidence of need of cognitive therapeutic intervention, as demonstrated by mild or greater cognitive deficiencies on an objective screening measure * reads and writes english * able to give informed consent * willing and able to attend 5 weekly group sessions and participate in pre and post-evaluation that will take place on the ucla campus exclusion criteria: * evidence of uncontrolled depression

Keywords: reduce cognitive complaints improve cognitive function post-treatment breast cancer patients
ducats trial: dynamic ultrasound to enhance understanding of carpal tunnel syndrome

Conditions: Carpal Tunnel

Summary: the purpose of this study is to learn if researchers can identify through ultrasound images and clinical assessment which subjects with carpel tunnel syndrome will do better following standard of care non-surgical or surgical treatment.


Eligibility criteria:
the following criteria must be answered yes to be enrolled: 1. does the patient have a clinical symptoms of carpal tunnel syndrome (cts)? 2. is the patient an adult between the ages of 21 and 80? 3. has the patient had symptoms of numbness or tingling for at least 4 weeks in at least two digits on one hand that include thumb, index, long or radial border of ring finger? 4. does the patient have a clinical diagnosis of carpal tunnel syndrome? 5. has the patient had and electrodiagnostic study (eds) or emg? (does not need to be positive\>) 6. is the patient able to understand and complete the study questionnaires and medical assessments in english? 7. is the patient clinically indicated for treatment with either a steroid injection or surgery as treatment for their cts? exclusion criteria the following questions if answered yes will exclude the patient from participation in the study. 1. has the patient had previous carpal tunnel release (ctr) or other volar wrist surgery on the hand? 2. does the patient have a known tumor, mass or deformity of the study hand or wrist? 3. does the patient have a previous history of steroid injection into the carpal tunnel (injection group only)? 4. does the patient have any of the following diagnoses or conditions: 1. cervical radiculopathy 2. rheumatoid arthritis or other inflammatory arthritis, including gout 3. osteoarthritis in the wrist 4. renal failure 5. morbid obesity (body mass index \>40) 6. sarcoidosis 7. peripheral nerve disease 8. diabetes 9. thyroid disease or other metabolic disorder 10. pregnancy 11. amyloidosis 12. major trauma (fractures or complete ligamentous tears) to the study hand or wrist? 5. is the patient a prisoner, institutionalized individual or someone who could be considered a vulnerable person, such as an individual with dementia?

Keywords: carpal tunnel
lansoprazole for subgroups of functional dyspepsia

Conditions: Functional Dyspepsia

Summary: pharmacotherapy for functional dyspepsia remains unsatisfactory. previous randomized trials reported conflicting results on clinical effectiveness of proton pump inhibitor in patients with functional dyspepsia. this study aims to examine whether lansoprazole 15mg is more effective than placebo for functional dyspepsia in taiwanese patients, and to investigate the association between subgroups of patients and therapeutic response.

this is a prospective double-blind randomized placebo-controlled trial. a total of 450 dyspeptic adult patients, who are diagnosed with functional dyspepsia in accordance with rome iii criteria, are randomly allocated in a 1:1 proportion to receive either lansoprazole 15mg or placebo once daily for 8 weeks. primary outcome is complete relief of dyspeptic symptoms. secondary outcomes include significant symptomatic relief, improvement of dyspepsia severity, and health-related quality of life. we use a multiple logistic regression analysis to investigate whether dyspepsia subgroups are associated with different therapeutic responses.

Eligibility criteria:
inclusion criteria: * dyspeptic adult outpatients * characteristic dyspeptic symptoms according to rome iii criteria (bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning) * upper gastrointestinal endoscopy excluding structural diseases exclusion criteria: * aged less than 20 years old, * organic lesions such as peptic ulcer, tumor of any kind, stricture or structural deformity, erosive esophagitis, or vasculopathy on endoscopy * typical and predominant reflux symptoms (heartburn or acid regurgitation) * comorbidity with malignancy, diabetes mellitus, liver cirrhosis, renal failure, or porphyria * history of intra-abdominal surgery * concurrent use of aspirin, non-steroidal anti-inflammatory drug or proton pump inhibitor * history of allergy or severe side effects to lansoprazole * pregnant or lactating women.

Keywords: functional dyspepsia lansoprazole placebo effect
elifewithibd - living with intention, fullness and engagement with inflammatory bowel disease (online)

Conditions: Inflammatory Bowel Diseases

Summary: this study aims to test the acceptability and preliminary efficacy of an online intervention (elifewithibd) developed for people with inflammatory bowel disease (ibd). the elifewithibd intervention is an adaptation of the lifewithibd program (delivered in an in-person group format; trindade et al., 2021), being an act, mindfulness, and compassion-based intervention. the elifewithibd intervention comprises nine sessions focusing on education about ibd, the functioning of the mind, emotions, and fatigue; acceptance of internal experiences; willingness; emotion regulation; values clarification; committed action; mindfulness; compassion; and gratitude. these topics are addressed through videos with therapists, texts, and experiential exercises.


Eligibility criteria:
inclusion criteria: * aged between 18 and 65; * ibd diagnosis (at least from 6 months prior); * regular access to a computer with internet; * able to write and read in portuguese, and give informed consent. exclusion criteria: * diagnosis of a psychiatric disorder (major depressive disorder, psychotic disorder, bipolar disorder, substance abuse), or suicidal ideation (assessed by the patient health questionnaire-9); * current psychotherapy use; * pregnancy.
tiagabine for the treatment of cocaine dependence - 1

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to assess tiagabine for the treatment of cocaine dependence.

to assess the efficacy and safety of tiagabine in reducing cocaine use in subjects with cocaine dependence. it is hypothesized that tiagabine treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (be). this is a double-blind, placebo-controlled, parallel-group design study, in which, after screening and a 2-week baseline assessment period, subjects will be equally randomly assigned to 1 of 2 treatment groups, tiagabine or matched placebo.

Eligibility criteria:
inclusion criteria: must be at least 18 years of age and be seeking treatment for cocaine dependence. have the ability to understand, and having understood, provide written informed consent. if female, agree to use a method of birth control as indicated by the clinician. please contact the participating site in your area for more information. exclusion criteria: please contact the participating site in your area for more information.

Keywords: cocaine dependence
comparison of analgesic efficacy and occurrence of emesis among different background infusion and bolus administration regimens of fentanyl based intravenous patient-controlled analgesia in patients after laparoscopic assisted gastrectomy - a randomized blind study -

Conditions: The Patients With Gastric Cancer Who Are Scheduled to Receive Laparoscopy Assisted Gastrectomy

Summary: fentanyl based intravenous patient controlled analgesia(pca)is popular method for postoperative pain control, but information regarding optimal dose of fentanyl in iv pca is currently lacking. we thus determine appropriate dose of fentanyl (bolus dose and background infusion rate) for effective pain control with minimal side effects such as nausea and vomiting


Eligibility criteria:
inclusion criteria: * age between 20 and 70 * asa class i and ii * gastric cancer patients who are scheduled to receive laparoscopic gastrectomy exclusion criteria: * cardiovascular disease(uncontrolled hypertension, unstable angina, congestive heart failure, etc.) * renal failure * liver failure * chronic drug or alcohol abuser * anti-cancer chemotherapy * chronic opioid use * use of antiemetics within 24hrs for nausea and vomiting

Keywords: intravenouspca, fentanyl, postoperative pain, laparoscopic gastrectomy
enoxaparin versus unfractionated heparin in pci

Conditions: Coronary Artery Disease

Summary: enoxaparin 0.75mg/kg bw is not inferior to weight adjusted unfractionated heparin as anticoagulation for pci


Eligibility criteria:
inclusion criteria: * pci for stable ischemia or acs exclusion criteria: * cardiogenic shock, * pretreatment with study drugs, * lack of informed consent

Keywords: enoxaparin, heparin, hemorrhages
evaluation of fusion rate using k2m vesuvius® demineralized fibers with k2m everest® spinal system

Conditions: Spinal Stenosis; Spondylolisthesis; Degenerative Disc Disease

Summary: the purpose of this study is to evaluate fusion status and patient outcomes observed from use of the vesuvius demineralized fibers with the everest spinal system as compared to the literature reported outcomes of spinal fusion using autograft with posterior stabilization.


Eligibility criteria:
inclusion criteria: * diagnosis of non-cervical spinal stenosis; spondylolisthesis (grade 1 or 2); and/or degenerative disc disease (ddd) with one or two contiguous levels requiring surgical intervention between l1-s1. qualified patients will be confirmed for inclusion by patient history and radiographic studies * willing and able to comply with the requirements of the protocol including follow-up requirements * willing and able to sign a study specific informed consent * skeletally mature and i 18 years old at time of enrollment exclusion criteria: * previous spine surgery at the index level * previous posterior spine surgery (e.g., posterior decompression) that destabilizes the lumbar spine * active systemic infection or infection at the operative site * co-morbid medical conditions of the spine or upper/lower extremities that may affect the lumbar spine neurological and/or pain assessment * metabolic bone disease such as osteoporosis and osteopenia that contradicts spinal surgery * history of an osteoporotic fracture * history of an endocrine or metabolic disorder (e.g., paget's disease) known to affect bone and mineral metabolism * taking medications that may interfere with bony/soft tissue healing including chronic steroid use * known allergy to titanium or cobalt chrome * rheumatoid arthritis or other autoimmune disease or a systemic disorder such as hiv, active hepatitis b or c, or fibromyalgia * insulin-dependent type 1 or type 2 diabetes * medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion * pregnant, or intends to become pregnant, during the course of the study * severe obesity (body mass index \> 40) * physical or mental condition (e.g., psychiatric disorder, senile dementia, alzheimer's disease, alcohol or drug addiction) that would interfere with patient self-assessment of function, pain, or quality of life. * involved in current or pending spinal litigation where permanent disability benefits are being sought * incarcerated at the time of study enrollment * current participation in an investigational study that may impact study outcomes

Keywords: spinal stenosis spondylolisthesis degenerative disc disease spinal fusion allograft interbody fusion
predicting outcomes for covid-19 using sonography

Conditions: COVID-19; Pneumonia, Viral

Summary: this study seeks to investigate the role of lung ultrasound in caring for covid-19 positive patients and whether it can be used to predict patient deterioration. this information will be vital for healthcare workers who seek to identify covid-19 pneumonia or patients at risk for deterioration early in the disease course.

as covid-19 continues to stress hospital-based resources (including personal protective equipment, ancillary staff availability, and imaging study utilization), it is important to assess whether alternative methods for evaluating patients can be utilized to appropriately triage and care for covid-positive patients. current limitations of caring for patients with covid-19 include the exposure of ancillary healthcare workers (including radiological technicians) and the time/resources required to decontaminate traditional radiological equipment such as x-ray or computerized tomography (ct) machines. point-of-care ultrasound (pocus) has the potential to transform healthcare delivery due to its diagnostic and therapeutic expediency. it can be quickly performed at the bedside by experienced clinicians. it it has been shown to reliably and accurately diagnose patients with a variety of lung diseases, including pneumonia. this study seeks to investigate the role of lung ultrasound in caring for covid-19 positive patients and whether it can be used to predict patient deterioration. this information will be vital for healthcare workers who seek to identify the virus or patients at risk for deterioration early in the disease course. moreover, it has the potential to reduce the need for x-rays or cts for covid-19 patients, which has the potential to alleviate a significant burden currently being placed on the healthcare system.

Eligibility criteria:
inclusion criteria: * any adult (18 or more years of age) presenting to the emergency department with symptoms suspicious for covid-19 * this individual underwent evaluation for covid-19 via a nasopharyngeal rt-pcr * this individual received a lung ultrasound by the study authors within 28 days from initial evaluation exclusion criteria: * any individual who did not receive a lung ultrasound within 28 days from initial evaluation for covid-19 related illness
effectiveness of digital manipulation of thyroid cartilage and fluency shaping therapy for the management of stuttering in adult

Conditions: Developmental Stuttering

Summary: this study was conducted to determine the effectiveness of digital manipulation of thyroid cartilage for the management of stuttering in adult.there were three groups,group a received digital manipulation of thyroid cartilage (dmt),group b received fluency shaping therapy(fst),group c received combination of dmt,fst.

the purpose of speech therapy is to stop progression of stuttering while teaching the method to client how to cope efficiently his or her stuttering disorder. the goal of fluency shaping therapy to eliminate the severity of stuttering by adopting the specific pattern of speech production and also reduce negative reaction to stuttering by default). digital manipulation of thyroid cartilage decreases tension in vocal fold and reduces severity of stuttering and improves production of speech. dmt reduces unnecessary amount of tension in vocal tract and participant speaks with relax respiration,phonation, articulation and facilitate more fluent.in dmt subject speaks in natural way rather than in specific method in every situation.

Eligibility criteria:
inclusion criteria: * developmental stuttering * between age of 18 to 30 years * only male exclusion criteria: * language disorders * cluttering * neurological stuttering

Keywords: fluency shaping therapy digital manipulation stuttering communication
study of enterra programming with nocturnal cycling in gastroparetics

Conditions: Gastroparesis; Gastroparesis Nondiabetic; Gastroparesis Due to Diabetes Mellitus

Summary: the purpose of this research study is to evaluate if different enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures. participants in this study with existing enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits. participants will be involved in the study for up to six months after treatment assignment. programming parameters in the study are within currently approved labeling.


Eligibility criteria:
in order to be eligible to participate in this study, a participant must meet all of the following criteria: 1. completed informed consent process with signed and dated informed consent form; 2. stated willingness to comply with all study procedures and availability for the duration of the study; 3. male or female, aged ≥18 or ≤70 at time of informed consent; 4. currently implanted with the enterra® therapy system (enterra® ii 37800 neurostimulator); 5. high ges output defined as remaining pulse generator expected life of \> 9 months from enrollment and less than 4 years from the time of implant; 6. stable gastroparesis symptoms, in the opinion of the investigator; 7. on stable medical therapy for gastroparesis symptoms; 8. on stable supplemental nutritional support during the month prior to enrollment; 9. english language comprehension to complete study-required assessments; 10. reliable access to internet-connected smart device(s) to complete study-required assessments. a participant who meets any of the following criteria will be excluded from participation in this study: 1. post-surgical gastroparesis (e.g., fundoplication, bilroth i or ii) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator; 2. subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night; 3. subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning; 4. subjects without a regular and defined sleep schedule; 5. pregnancy, or subject that intends to become pregnant during participation in the study; 6. chemical dependency; 7. enterra lead impedance measurements ≥ 700 ohms at screening visit; 8. life expectancy \< 1 year from conditions other than gi diseases; 9. subjects with an underlying disease leading to follow-up by mri outside of current mr conditional indications; 10. participation in other clinical studies; 11. subjects involved in current or past medical-related litigation; 12. subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements.

Keywords: gastric electrical stimulation gastroparesis
sustained humoral and cell-mediated immunogenicity of covid-19 vaccines in patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the aim of this study is to determine the impact of systemic immunosuppression on sustained antibody covid-19 concentrations in patients with ibd who received a covid-19 vaccine.


Eligibility criteria:
a patient will be eligible for inclusion in this study if he or she meets all the following criteria: * patient is between the ages of 18-85 years, inclusive * patient has a history of ulcerative colitis (uc), or crohn's disease diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria * on one of the following treatment regimens for at least three months at the time of immunization and continued same therapy at the time of recruitment. should be on stable doses defined as: group a should have taken a dose of medication within the past week; group b infliximab within the previous 8 weeks, golimumab within the previous 4 weeks, adalimumab within the previous 2 weeks, or certolizumab within the previous 4 weeks; those on combination therapy in group b will have taken azathioprine or methotrexate within the past week. group c ustekinumab at least within the previous 4 weeks. those on combination therapy in group c will have taken azathioprine or methotrexate within the past week; group d vedolizumab at least within the previous 4 weeks. those on combination therapy in group d will have taken azathioprine or methotrexate within the past week * group a non-biologic group: mesalamine monotherapy or thiopurine monotherapy * group b: anti-tnf therapy group: on maintenance therapy infliximab (at least 5mg/kg every 8 weeks), golimumab (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly combination therapy anti- tnf combination therapy group: on anti-tnf therapy as described above along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6mp 0.5mg/kg at least 40% of the group; approximately 40-50% of the group will be combination therapy * group c: ustekinumab on either ustekinumab monotherapy or combination therapy with methotrexate or azathioprine * group d: vedolizumab therapy group: vedolizumab therapy: on either vedolizumab monotherapy or combination therapy with methotrexate or azathioprine * patient received at least two doses of mrna covid-19 vaccine per standard of care a patient will not be eligible for inclusion in this study if he or she meets all the following criteria: * patient cannot or will not provide written informed consent * unable to provide appropriate informed consent due to being illiterate or impairment in decision-making capacity * received a covid-19 booster within the previous 28 days